Changzhou Forest-Pharm Co., Ltd is private-owned company which is established in 2009. We are working on process R&D, manufacture and trade of advanced pharmaceutical intermediates and APIs.
Our main products are Nizatidine, Famotidine, Benzydamine HCL and relative intermediates. The plant is located in Binhai, Yancheng, which is in compliance with cGMP guidance and is certified by ISO9001:2008 and ISO14001:2004, OHSAS18001:2007.
We have built our own R&D center and Kilo-grade laboratory, which is locates in Changzhou. we are focusing on manufacturing of tyrosine kinase inhibitor (such as Lapatinib, Dasatinib, Bosutinib, Tofacitinib, Ibrutinib, Ceritinib, Afatinib, Lenvatinb, Osimertinib, neratinib) and relative pharmaceutical intermediates, etc. Also some other new drugs with good clinic reputation such as Niraparib and Ritonavir also are under bench investigation.
In recent years, we have strengthened talent reserves and team culture, and established constructive cooperation with many domestic institutes and Universities. Products have been exported to many countries, and the company also become the raw materials supplier of many large pharmaceutical enterprises in the Domestic market.
We can not only provide various kind of API and its advanced intermediates, but also can provide technique and documents support. We are looking forward to establish more long-term cooperation with other worldwide end-user.
Our main products are Nizatidine, Famotidine, Benzydamine HCL and relative intermediates. The plant is located in Binhai, Yancheng, which is in compliance with cGMP guidance and is certified by ISO9001:2008 and ISO14001:2004, OHSAS18001:2007.
We have built our own R&D center and Kilo-grade laboratory, which is locates in Changzhou. we are focusing on manufacturing of tyrosine kinase inhibitor (such as Lapatinib, Dasatinib, Bosutinib, Tofacitinib, Ibrutinib, Ceritinib, Afatinib, Lenvatinb, Osimertinib, neratinib) and relative pharmaceutical intermediates, etc. Also some other new drugs with good clinic reputation such as Niraparib and Ritonavir also are under bench investigation.
In recent years, we have strengthened talent reserves and team culture, and established constructive cooperation with many domestic institutes and Universities. Products have been exported to many countries, and the company also become the raw materials supplier of many large pharmaceutical enterprises in the Domestic market.
We can not only provide various kind of API and its advanced intermediates, but also can provide technique and documents support. We are looking forward to establish more long-term cooperation with other worldwide end-user.
